IBT completed its pivotal Phase 3 trial for IBP-9414, showing a 27% reduction in mortality among preterm infants, and is preparing a BLA for FDA submission in 2025. Financials reflect a net loss of SEK 136.9 million, with sufficient liquidity for upcoming regulatory milestones.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.